VIR Statistiques clés
Haut
9.09
Ouverture
8.82
Volume
1.68M
Bas
8.77
Clôture précédente
8.69
Valeur négociée
14.99M
Plus haut 52 sem.
11.66
Vol. relatif
1.022
Amplitude (%)
3.62%
Plus bas 52 sem.
4.16
Taux de rotation
1.00%
Cap. Marché
1.46B
PER (TTM)
--
PER (Annuel)
2.234
P/B
1.8
P/S
22.38
Bénéfice par action (BPA)
-3.137
Dividende (TTM)
0
Rendement du dividende
0.00%
Actions en circulation
168.65M
Devise
USD
VIR Performance du Prix
7 jour
30 jour
90 jour
180 jour
Depuis le début de l’année
1 An
VIR Répartition des flux monétaires
VIR Volume quotidien des ventes à découvert
VIR Historique du short interest
VIR Aperçu de l’action
As of 2026-07-28, the Vir Biotechnology, Inc. (VIR) stock price today is 8.8. Based on this price, the company has a market capitalization of $1.46B, with a P/E ratio of --.
On 2026-07-28, VIR traded between 8.77 and 9.09. Today’s stock price is 0.34% above the daily low and 3.19% below the daily high, placing VIR proche du bas de its most recent trading range.
Trading volume currently stands at 1.68M, compared with an average daily volume of 1.65M. This suggests that trading activity is à peu près conforme à son niveau habituel than usual.
Over the past year, Vir Biotechnology, Inc. shares have traded between 4.16 and 11.66. At today’s price, VIR is 111.54% above its 52-week low and 24.53% below its 52-week high.
VIR Actualités liées
À propos VIR
Nom l'entreprise
Vir Biotechnology, Inc.
Secteur
Health Technology
Industrie
Biotechnology
Exchanges
Nasdaq
Nombre d’employés
367
Taille du lot
100
Site officiel
Devise
USD
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Related Stocks
VIR FAQ
© 2026 CoinGlass, all rights reserved
